5. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet, 2007, 23(5):243-249.
[2]
10. Iorio MV, Croce CM. MicroRNA dysregulation in cancer:diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 2012, 4(3):143-159.
[3]
11. Liu MX, Siu MK, Liu SS, et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget, 2014, 5(4):944-958.
[4]
12. Fang C, Zhao Y, Guo B. MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem, 2013, 114(7):1457-1463.
[5]
6. Robin TP, Smith A, McKinsey E, et al. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of microRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res, 2012, 10(8):1098-1108.
[6]
7. Dylla L, Jedlicka P. Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One, 2013, 8(4):e63032.
[7]
14. Won KY, Kim YW, Kim HS, et al. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol, 2013, 44(8):1648-1655.
[8]
16. Sticht C, Hofele C, Flechtenmacher C, et al. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br J Cancer, 2005, 92(4):770-774.
[9]
1. Windsor R, Strauss S, Seddon B, et al. Experimental therapies in Ewing's sarcoma. Expert Opin Invest Drugs, 2009, 18(2):143-159.
[10]
2. Teicher BA, Bagley RG, Rouleau C, et al. Characteristics of human Ewing/PNET sarcoma models. Ann Saudi Med, 2011, 31(2):174-182.
[11]
4. Borinstein SC, Beeler N, Block JJ, et al. A Decade in Banking Ewing Sarcoma:a Report from the Children's Oncology Group. Front Oncol, 2013, 3:57.
[12]
8. Dylla L, Moore C, Jedlicka P. MicroRNAs in Ewing Sarcoma. Front Oncol, 2013, 3:65.
13. Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol, 2005, 3(3):e85.
[15]
15. Muller D, Millon R, Théobald S, et al. Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. Br J Cancer, 2006, 94(7):1041-1044.
[16]
17. Li Y, Bai H, Zhang Z, et al. The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2. Mol Cells, 2014, 37(3):213-219.
[17]
18. Phung B, Sun J, Schepsky A, et al. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One, 2011, 6(8):e24064.
[18]
19. Landuzzi L, De Giovanni C, Nicoletti G, et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol, 2000, 157(6):2123-2131.
[19]
20. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One, 2009, 4(3):e4998.
[20]
21. Ikeda AK, Judelson DR, Federman N, et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther, 2010, 9(3):653-660.
[21]
3. Zhang Z, Huang L, Yu Z, et al. Let-7 a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6. DNA Cell Biol, 2014, 33(3):136-147.
